Payment overview · 2025
General Payments
$330.01
18 reported records · 11 companies
Healthcare provider profile · identity verified
John William Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GONZALES, TX · NPI 1881857498
Verified facts
What the public records show
CMS Open Payments records show John William Thomas, M.D. received $330.01 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.12 | 22.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.63 | 14.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.85 | 11.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.38 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.06 | 7.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.75 | 7.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.81 | 6.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.25 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.22 | 5.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.32 | 5.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.62 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $330.01 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.67 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.38 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 129 |
| Furosemide | Furosemide | 392 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 78 |
| Losartan Potassium | Losartan Potassium | 318 | 77 |
| Gabapentin | Gabapentin | 312 | 83 |
| Potassium Chloride | Potassium Chloride | 258 | 54 |
| Tramadol Hcl | Tramadol Hcl | 238 | 68 |
| Metformin Hcl | Metformin Hcl | 202 | 59 |
| Carvedilol | Carvedilol | 186 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 184 | 50 |
| Valsartan | Valsartan | 183 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 33 |
| Lisinopril | Lisinopril | 146 | 42 |
| Celecoxib | Celecoxib | 145 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 41 |
| Trazodone Hcl | Trazodone Hcl | 134 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 22 |
| Omeprazole | Omeprazole | 127 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 22 |
| Meloxicam | Meloxicam | 120 | 37 |
| Xarelto | Rivaroxaban | 120 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Ozempic | Semaglutide | 115 | 20 |
| Eliquis | Apixaban | 111 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 37 |
| Simvastatin | Simvastatin | 110 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 34 |
| Sertraline Hcl | Sertraline Hcl | 106 | 24 |
| Clonazepam | Clonazepam | 96 | 16 |
| Naproxen | Naproxen | 93 | 40 |
| Donepezil Hcl | Donepezil Hcl | 91 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 82 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 26 |
| Jardiance | Empagliflozin | 78 | 15 |
| Montelukast Sodium | Montelukast Sodium | 75 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 24 |
| Alprazolam | Alprazolam | 69 | 13 |
| Famotidine | Famotidine | 66 | 21 |
| Cephalexin | Cephalexin | 63 | 46 |
| Spironolactone | Spironolactone | 63 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 19 |
| Lorazepam | Lorazepam | 62 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 14 |
| Allopurinol | Allopurinol | 57 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | suppressed |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 16 |
| Baclofen | Baclofen | 47 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 13 |
| Rybelsus | Semaglutide | 45 | 13 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Telmisartan | Telmisartan | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 14 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Atenolol | Atenolol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 20 |
| Topiramate | Topiramate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Novolin R | Insulin Regular, Human | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Prednisone | Prednisone | 23 | 20 |
| Lactulose | Lactulose | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 16 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 11 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Linzess | Linaclotide | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Constulose | Lactulose | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Clonidine | Clonidine | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $330.01 · 18 records | Lilly USA, LLC | CAPLYTA, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PROQUAD, REXULTI, ROTATEQ, VAXELIS, VAXNEUVANCE, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error